Unraveling the Complexities of HER2 Gastric Cancer: A Single-Cell Resolution Study
HER2-positive gastric cancer is a formidable disease, accounting for a significant portion of advanced cases and often treated with HER2-targeted therapies. While trastuzumab deruxtecan has shown promise, the battle against this cancer is far from over. Most patients either don't respond at all or eventually develop resistance, leaving researchers and clinicians searching for answers.
A groundbreaking study published in Precision Clinical Medicine (DOI: 10.1093/pcmedi/pbaf038) on December 19, 2025, offers a fascinating glimpse into the intricate world of drug resistance in advanced gastric cancer. Researchers from Peking University Cancer Hospital and their collaborators have delved into the single-cell resolution of treatment-induced cellular evolution, revealing surprising insights.
The study analyzed tumor biopsies from patients enrolled in the phase II DESTINY-Gastric06 trial, employing single-cell RNA sequencing to track the dynamic changes in cancer cells and their immune environment during treatment with trastuzumab deruxtecan. This meticulous approach allowed them to identify the molecular drivers of both primary and acquired resistance, shedding light on potential biomarkers and therapeutic targets.
The researchers analyzed nearly 92,000 individual cells from gastric cancer biopsies, collected at different stages of treatment. By examining epithelial tumor cells at the single-cell level, they uncovered distinct transcriptional programs associated with various resistance stages. Tumors exhibiting primary resistance were found to be enriched with metabolic pathways linked to glycolysis and lipid metabolism. Among these, MUC3A emerged as a key player. High MUC3A expression predicted shorter progression-free survival and experimentally demonstrated reduced sensitivity to trastuzumab deruxtecan by hindering drug binding to HER2-positive cells.
In contrast, acquired resistance followed a different path. As treatment progressed, tumor cells downregulated HER2 and cell-cycle genes while upregulating CST3, a natural inhibitor of lysosomal proteases crucial for drug activation. Functional assays confirmed that CST3 dampens the drug's effectiveness, allowing tumor cells to survive despite ongoing therapy.
The study's findings extended beyond tumor-intrinsic changes, revealing a dynamic tumor microenvironment. Initial treatment enhanced immune-cell infiltration and antigen presentation, but resistant tumors shifted towards an immunosuppressive state, marked by the reactivation of transforming growth factor-beta signaling and increased PD-1 expression on immune cells. This coordinated cellular, metabolic, and immune adaptation explains the short-lived responses and highlights the need for dynamic biomarkers in treating advanced gastric cancer.
One of the senior investigators emphasized the complexity of resistance, stating, 'Resistance to highly effective therapies rarely stems from a single factor. By examining tumors at the single-cell level, we witnessed how different cancer cell populations adapt uniquely – some blocking drug binding early on, others disabling drug activation, or reshaping the immune environment over time. This layered view of resistance helps us understand the challenges of treatment and underscores the importance of personalized, dynamic biomarkers.'
The study's implications are far-reaching. Measuring MUC3A expression could help identify patients unlikely to benefit from trastuzumab deruxtecan upfront, enabling more precise treatment selection. Targeting CST3 or restoring lysosomal drug processing may be key to overcoming acquired resistance. Additionally, the observed shift towards immune suppression suggests that combining trastuzumab deruxtecan with immunotherapies or agents targeting TGF-β signaling could be a promising strategy. Most importantly, this research demonstrates how single-cell technologies can guide personalized combination therapies by revealing the intricate ways tumors adapt under therapeutic pressure.
This study serves as a powerful reminder that the battle against HER2 gastric cancer is a complex one, requiring a deep understanding of cellular evolution and resistance mechanisms. By unraveling these complexities at the single-cell resolution, researchers are paving the way for more effective and personalized treatment strategies, offering renewed hope for patients facing this challenging disease.
